Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094067 · ClinicalTrials.gov registry record · Phase 2
Tezosentan in Patients With Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01094067: Clinical Trial Phase 2 study, sponsored by Idorsia Pharmaceuticals.
NCT01094067 is a Phase 2 study that was terminated before completion, run by Idorsia Pharmaceuticals. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01094067, a Phase 2 study, was terminated before completion, sponsored by Idorsia Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or a combination of both.
Interventions
- OTHER Placebo
- DRUG ACT-050089
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-09-01 |
| Est. Completion | 2011-09-01 |
| Phase | Phase 2 |
Why NCT01094067 stopped before completion
NCT01094067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01094067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01094067 about?
NCT01094067 is a clinical study titled "Tezosentan in Patients With Pulmonary Arterial Hypertension". Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or a com...
What is the current status of trial NCT01094067?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2010-09-01. Estimated completion is 2011-09-01.
What interventions are being tested in trial NCT01094067?
The interventions under investigation include: Placebo (OTHER), ACT-050089 (DRUG).
Who is sponsoring clinical trial NCT01094067?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01094067's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI